Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

"Novo Nordisk plans new study for CagriSema, targets 2026 submission" was originally created and published by Pharmaceutical ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Novo Nordisk's Karsten Munk Knudsen is targeting 800 million obese people globally.

Novo Nordisk AS (NVO) reports a strong 26% increase in sales and operating profit, with significant growth in obesity care ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...